← FDA DRUG APPROVALS

FDA ANDA · ANDA088869

THIORIDAZINE HYDROCHLORIDE

Sponsor: WATSON LABS

APPLICATION
ANDA088869
TYPE
ANDA
ORIGINAL APPROVAL
1985-06-28
LATEST ACTION
2017-02-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

THIORIDAZINE HYDROCHLORIDEDiscontinued
THIORIDAZINE HYDROCHLORIDE 150MG · TABLET · ORAL

Approval history

2017-02-23Labeling · Supplement 13 · standardAP
2015-11-03Labeling · Supplement 12AP
1992-11-23Manufacturing (CMC) · Supplement 3AP
1992-11-23Manufacturing (CMC) · Supplement 4AP
1992-11-23Manufacturing (CMC) · Supplement 7AP
1992-11-23Manufacturing (CMC) · Supplement 5AP
1991-01-28Manufacturing (CMC) · Supplement 9AP
1990-08-09Labeling · Supplement 10AP
1990-06-29Manufacturing (CMC) · Supplement 2AP
1985-06-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →